BenevolentAI

Accelerate scientific breakthroughs with AI

Hiring: #London

[BenevolentAI @benevolent_ai]

The Goldman Sachs 45th Annual Global Healthcare Conference is fast approaching.

Our CEO, Dr Joerg Moeller, and CFO, Catherine Isted ACMA, will be onsite 11-13 June and will feature in a fireside chat on 13 June, 08:40 AM EDT.

More info: https://t.co/eGiLa0O7cX

[BenevolentAI @benevolent_ai]

As part of our collaboration, we’re delighted to announce that AstraZeneca has added a novel target for Heart Failure to its discovery portfolio.

The target was discovered using BenevolentAI’s AI-drug discovery platform.

Read more:

https://t.co/Wpw7xGJEyL

[Emerj AI Research @Emerj]

Today on the '#AIinHealthcare and #LifeSciences' podcast, @Benevolent_AI Chief Scientific Officer Anne Phelan discusses AI's impact on #DrugDiscovery:

https://t.co/doeCCoTz7B

#AI #Healthcare #PrecisionMedicine

[BenevolentAI @benevolent_ai]

At BenevolentAI, we’re proud of our Target Identification offering. It has yielded great results for partners, as well as for our own pipeline.

🎯 Quickly predict and evaluate the relevance, novelty and progressability of potential drug targets.

#AI #TargetIdentification

[Anthropic @AnthropicAI]

UK-based TechBio company @benevolent_ai uses Claude to evaluate datasets, annotate evidence for model fine-tuning, and textualize non-literature data modalities for its models to reason over.

[BenevolentAI @benevolent_ai]

📢We’re pleased to share positive topline data from our Phase 1a clinical study of BEN-8744 in healthy volunteers
📢This is being developed as a potential first-in-class treatment for moderate to severe ulcerative colitis
👉 Read more here https://t.co/bhd99ztTzb

[BenevolentAI @benevolent_ai]

Today BenevolentAI shares its 2023 Annual Report. Download the report on our website

Last week we presented our preliminary results:
👉 Watch a recording of the analyst briefing https://t.co/RS9iLCGzSW

👉 Watch our CEO discuss our 2024 Company outlook https://t.co/X2fL5iBpgH

[BenevolentAI @benevolent_ai]

👉Today BenevolentAI announced its preliminary results for the year ending 31st December 2023. Follow link below for full announcement.
👉At 1pm GMT today we will host a webcast analyst briefing, a recording will be available on our website shortly after.
https://t.co/qbrpRVsDbQ

[BenevolentAI @benevolent_ai]

📢Thanks for including us in this series @_singercm ! Click here to listen to the brilliant "AI in Action" podcast featuring our COO and Co-Founder Ivan Griffin

[Singer Capital Markets @_singercm]

'𝗔𝗜 𝗶𝗻 𝗔𝗰𝘁𝗶𝗼𝗻' 𝗣𝗼𝗱𝗰𝗮𝘀𝘁 𝗦𝗲𝗿𝗶𝗲𝘀🎙️ - Hear from a range of companies at the forefront of #AI #innovation who reveal valuable #insights into their strategic use and deployment of AI💡 - Series now available 👉 https://t.co/2ZmqHHQhYH #podcast #finance #tech

[BenevolentAI @benevolent_ai]

Today we’re announcing Joerg Moeller, an accomplished Pharma R&D leader and champion of the application of AI to drug discovery, as our new CEO
💫Joerg brings a wealth of experience to BenevolentAI following an extensive career in R&D
👇Read more here! https://t.co/uPkugfbWcs

[BenevolentAI @benevolent_ai]

Read the article here: https://t.co/5GvParZZod

[BenevolentAI @benevolent_ai]

📰Thanks @PharmaScrip for your piece following Chair + Acting CEO Dr. François Nader’s presentation at JPM last week.

💫Click below to find out about growth within the AI-driven drug discovery sector, what this means for BenevolentAI, and our pipeline of first-in-class drugs.

[BenevolentAI @benevolent_ai]

📢 Our Chair and Acting CEO Francois Nader presented at last week's 42nd Annual J.P.Morgan Healthcare Conference - you can now watch the presentation on our website, visit the link below 👇

https://t.co/qbrpRVs5mi

[BenevolentAI @benevolent_ai]

Visit the link below to watch it live. A recording will also be made available on our website shortly after. https://t.co/jt9TMTwqHB

[BenevolentAI @benevolent_ai]

Watch BenevolentAI’s presentation at the 42nd Annual J.P.Morgan Healthcare ConferenceAfter a busy week at the conference, we’re closing off with a presentation and Q&A session from Chair and Acting CEO Dr. François Nader tomorrow, Thursday 11th January, at 08:15 PST (16:15 GMT).

[BenevolentAI @benevolent_ai]

👉Are you attending? Get in touch if you’d like to arrange a meeting - send an email to [email protected], [email protected], comment below or send us a DM.

[BenevolentAI @benevolent_ai]

BenevolentAI at the 42nd Annual J.P.Morgan Healthcare Conference

💫 We’re excited that members of BenevolentAI’s Executive Leadership Team are heading to San Francisco for the industry’s largest and most prestigious healthcare conference.

[BenevolentAI @benevolent_ai]

🔈 As a company at the forefront of using AI in drug discovery, we are looking forward to connecting with investors and companies alike who want to learn more about BenevolentAI and the work we do in this fast growing area of science.

[BenevolentAI @benevolent_ai]

📣 Francois Nader, MD, MBA and Acting CEO, will present a Company overview and participate in a Q&A session on Thursday 11th January at 08:15 PST (16:15 GMT) - a recording will be made available on our website in due course.

[BenevolentAI @benevolent_ai]

2023 has been a year of transition for BenevolentAI. As we head into 2024, we remain committed to our mission to unite science and technology to serve patients with complex diseases.

[BenevolentAI @benevolent_ai]

Today, our Chair and Acting CEO Dr Francois Nader shared a letter with our shareholders that looks back at 2023 and sets out our priorities for the year ahead.

Head to our website to read the letter in full
👉https://t.co/qbrpRVs5mi